Research Topics
| CHRISTOPHER PLOWESummaryAffiliation: University of Maryland Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samplesMeera Venkatesan
Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD, USA
Malar J 11:41. 2012..This study was undertaken to determine whether CF11 columns could be adapted to isolate Plasmodium falciparum DNA from parasitized whole blood and achieve current quantity and purity requirements for Illumina sequencing...- The rationale and plan for creating a World Antimalarial Resistance Network (WARN)Carol Hopkins Sibley
Malar J 6:118. 2007..WARN will serve as a public resource to guide antimalarial drug treatment and prevention policies and to help confirm and characterize the new emergence of new resistance to antimalarial drugs and to contain its spread... - World Antimalarial Resistance Network (WARN) IV: clinical pharmacologyKaren I Barnes
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Malar J 6:122. 2007.... - World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugsRic N Price
International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
Malar J 6:119. 2007..This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed... - A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDaShannon L Takala
Center for Vaccine Development, University of Maryland School of Medicine, HSF1 480, Baltimore, Maryland 21201, USA
Malar J 5:31. 2006..Methods are needed to monitor genetic diversity in polymorphic vaccine antigens, but determining which genetic variants of such antigens are present in infected individuals is complicated by the frequent occurrence of mixed infections... - Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccineAmed Ouattara
Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, Mali
Malar J 9:175. 2010.... - Antimalarial drug resistance in Africa: strategies for monitoring and deterrenceC V Plowe
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, MA 21201, USA
Curr Top Microbiol Immunol 295:55-79. 2005..In the absence of an ideal antimalarial combination regimen, different treatment alternatives are appropriate in different settings. But where chloroquine has failed, policy changes are long overdue and action must be taken now... - Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective studyChristopher V Plowe
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, MD 21044, USA
BMJ 328:545. 2004..To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993... - Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacyC V Plowe
Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA
Am J Trop Med Hyg 64:242-6. 2001..Modifications of the protocol for monitoring antimalarial therapeutic efficacy are recommended... - Monitoring antimalarial drug resistance: making the most of the tools at handChristopher V Plowe
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
J Exp Biol 206:3745-52. 2003..This raises the intriguing possibility of rotating antimalarial drugs... - World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malariaChristopher V Plowe
Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, Maryland 21201, USA
Malar J 6:121. 2007.... - The evolution of drug-resistant malariaChristopher V Plowe
Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Trans R Soc Trop Med Hyg 103:S11-4. 2009.... - Return of chloroquine antimalarial efficacy in MalawiMiriam K Laufer
University of Maryland School of Medicine, Baltimore, MD 21201, USA
N Engl J Med 355:1959-66. 2006..CONCLUSIONS: Chloroquine is again an efficacious treatment for malaria, 12 years after it was withdrawn from use in Malawi. (ClinicalTrials.gov number, NCT00125489 [ClinicalTrials.gov].)... - Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South AmericaJoseph F Cortese
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
J Infect Dis 186:999-1006. 2002..This study highlights the importance of continent-wide malaria-control policies and suggests that the containment of resistance to the next generation of therapies may be feasible... - Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in MaliShannon L Takala
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
PLoS Med 4:e93. 2007.... - Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methodsShannon L Takala
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Am J Trop Med Hyg 76:855-9. 2007.... - Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in MalawiJames G Kublin
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
J Infect Dis 187:1870-5. 2003..The reintroduction of chloroquine, ideally in combination with another antimalarial drug, should be considered in areas where chloroquine resistance has declined and safe and affordable alternatives remain unavailable... - Impact of HIV-associated immunosuppression on malaria infection and disease in MalawiMiriam K Laufer
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA
J Infect Dis 193:872-8. 2006..Where malaria is common, the high incidence of fever found among immunosuppressed adults may lead to misclassification of illness episodes as malaria... - Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policiesMiriam K Laufer
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1 480, Baltimore, MD 21201, USA
Drug Resist Updat 7:279-88. 2004..The finding that drug resistance decreases with the removal of drug pressure could provide a new paradigm for malaria treatment policies in Africa... - Mechanisms of resistance of malaria parasites to antifolatesAric Gregson
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 Room 480, Baltimore, MD 21201, USA
Pharmacol Rev 57:117-45. 2005..Molecular epidemiological techniques for monitoring parasite drug resistance may contribute to development of strategies for prolonging the useful therapeutic life of this important class of drugs... - Observational cohort study of HIV-infected African childrenMiriam K Laufer
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
Pediatr Infect Dis J 25:623-7. 2006..Children identified through voluntary counseling and testing (VCT) represent a unique cohort that has not been previously described in the literature... - Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasitesMiriam K Laufer
Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
J Infect Dis 202:801-8. 2010..Chloroquine-susceptible parasites that predominate in Malawi likely represent a reexpansion of the susceptible parasites that survived in the population despite widespread drug pressure in the region... - Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trialKirsten E Lyke
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
PLoS ONE 5:e13490. 2010..The standard model relies on the bite of five infected mosquitoes to induce malaria. We examined the efficacy of malaria transmission using mosquitoes raised aseptically in compliance with current Good Manufacturing Practices (cGMPs)... - Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian childrenKirsten E Lyke
Center for Vaccine Development, University of Maryland at Baltimore, 685 W. Baltimore St, HSFI 480, Baltimore, MD 21201, USA
Infect Immun 74:5718-24. 2006..001) and the Sch(-) children (P < 0.001) who were 4 to 8 years old. We postulate that the Th2-enriched environment induced by schistosomiasis protects against malaria and alters the cytokine milieu during an actual infection... - Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malariaKirsten E Lyke
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Am J Trop Med Hyg 69:253-9. 2003.... - Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine developmentShannon L Takala
Howard Hughes Medical Institute and Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
Sci Transl Med 1:2ra5. 2009..This extreme diversity may pose a serious obstacle to an effective polyvalent recombinant subunit apical membrane antigen-1 vaccine... - Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malariaJames G Kublin
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
J Infect Dis 185:380-8. 2002..If this model is validated in other populations, it will finally be possible to use molecular markers for surveillance of antifolate-resistant P. falciparum malaria in Africa... - Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trialKirsten E Lyke
Center for Vaccine Development, University of Maryland, Baltimore, MD, United States
Vaccine 27:2171-6. 2009..These results provide evidence that complex immune responses can be induced by this vaccination strategy and add further impetus for the continuing clinical evaluation of this vaccine... - Malaria treatment efficacy among people living with HIV: the role of host and parasite factorsMiriam K Laufer
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Am J Trop Med Hyg 77:627-32. 2007.... - HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controlsKirsten E Lyke
The University of Maryland at Baltimore, Center for Vaccine Development, 685 W Baltimore St, HSF 480, Baltimore, MD 21201, USA
Infect Immun 73:5799-808. 2005..However, whether these immune responses to TRAP, CSP, and Exp-1 malarial proteins play a substantial role in protection remains a matter of controversy... - Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, MaliKirsten E Lyke
Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF 480, Baltimore, MD, USA
Vaccine 22:3169-74. 2004..This approach may be useful in assessing the suitability of potential sites for malaria vaccine trials... - Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian childrenKirsten E Lyke
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Am J Trop Med Hyg 73:1124-30. 2005..falciparum malaria was observed in children 9-14 years of age. We conclude that underlying schistosomiasis is associated with protection against clinical falciparum malaria in an age-dependent manner... - Monitoring and deterring drug-resistant malaria in the era of combination therapyMiriam K Laufer
Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
Am J Trop Med Hyg 77:160-9. 2007..The malaria research and control community should not fail to exploit this opportunity to apply the lessons of the last 50 years to extend the useful therapeutic lives of ACTs... - Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African childrenMonica Arman
Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
Am J Trop Med Hyg 77:943-6. 2007..001) but not with disease category (F(2,122) = 1.8, P = 0.17). Therefore platelet-mediated clumping in Malian P. falciparum isolates is primarily associated with high parasitemia and not with severe clinical manifestations of malaria... - A network to monitor antimalarial drug resistance: a plan for moving forwardCarol Hopkins Sibley
Department of Genome Sciences, University of Washington, Seattle, WA, USA
Trends Parasitol 24:43-8. 2008.... - Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera
Malaria Research and Training Center, University of Bamako, Bamako, Mali
PLoS ONE 3:e1465. 2008..The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria... - Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoesFabian Mendez
Escuela de Salud Publica, Universidad del Valle, Cali, Colombia
Am J Trop Med Hyg 77:438-43. 2007..23, P < 0.05). Low-level drug resistance mutations have the potential to enhance transmission of P. falciparum and spread resistant parasites... - Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in MalawiDavid J Bell
Department of Molecular and Biochemical Parasitology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
PLoS ONE 3:e1578. 2008..Here we compare the efficacy, safety and selection of resistance using SP or CQ+SP or artesunate (ART)+SP or AQ+SP for the treatment of uncomplicated falciparum malaria... - Pneumocystis pneumonia in HIV-positive adults, MalawiJoep J G van Oosterhout
University of Malawi College of Medicine, Blantyre, Malawi
Emerg Infect Dis 13:325-8. 2007..PcP incidence was highest in patients with the lowest CD4 counts, but PcP is uncommon compared with incidences of pulmonary tuberculosis and bacterial pneumonia... - Community permission for medical research in developing countriesDapa A Diallo
Department of Hematology, Malaria Research and Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Mali
Clin Infect Dis 41:255-9. 2005..Far from competing with the individual informed consent process, the process of obtaining community permission both initiated and facilitated the process of disclosure for individual informed consent... - Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malariaFraction K Dzinjalamala
Division of Pharmacology, University of Cape Town, Cape Town, South Africa
Am J Trop Med Hyg 72:267-72. 2005.... - Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of ResearchD Gray Heppner
Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
Vaccine 23:2243-50. 2005..Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine... - A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malariaDapa A Diallo
, University of Bamako, Bamako, Mali
Acta Trop 90:295-9. 2004..By this measure, HbC, a malaria-protective polymorphism with few deleterious consequences, does not appear to be associated with more frequent anemia than normal HbA in episodes of uncomplicated P. falciparum malaria... - Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, MaliDrissa Coulibaly
Malaria Research and Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Mali, Bamako, Mali, West Africa
Am J Trop Med Hyg 67:604-10. 2002.... - Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of BolivarCarmen E Contreras
Immunology Institute, School of Medicine, Central University, Caracas, Venezuela
Am J Trop Med Hyg 67:400-5. 2002..falciparum malaria in Bolivar, and an invasion of multi-resistant pathogens from Brazil. Despite national restrictions on the use of SP and chloroquine, genotypic resistance to these therapies remains widespread in Bolivar... - Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian childrenFraction K Dzinjalamala
University of Cape Town, Division of Clinical Pharmacology, K50 Old Main Building, Groote Schuur Hospital, Cape Town 7925, South Africa
Antimicrob Agents Chemother 49:3601-6. 2005..falciparum should be interpreted with caution and needs further validation... - Combination therapy for malaria: mission accomplished?Christopher V Plowe
Clin Infect Dis 44:1075-7. 2007 - Use of area under the curve to characterize transmission potential after antimalarial treatmentFabian Mendez
Escuela de Salud Publica, Universidad del Valle, Cali, Colombia
Am J Trop Med Hyg 75:640-4. 2006..Methods presented are applicable to both observational studies and clinical trials assessing the effect of therapies on transmission potential... - Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemiaHelen M Kyriacou
Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, UK
Mol Biochem Parasitol 150:211-8. 2006..These results suggest that var genes with DBLalpha1-like domains (Group A or B/A) may be implicated in the pathogenesis of cerebral malaria, while var genes with DBLalpha0-like domains promote less virulent malaria infections... - Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?Miriam K Laufer
Am J Trop Med Hyg 75:373-4. 2006 - Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controlsYacouba Cissoko
Bandiagara Malaria Project, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Malaria Research and Training Center, University of Bamako, Bamako, Mali
Am J Trop Med Hyg 75:199-204. 2006..A direct correlation between age and parasitemia and IgG antibodies to GPI was observed. In summary, higher levels of IgM and IgG antibodies to GPI in young children were associated with disease severity and were short-lived... - Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulenceAnne Marie Deans
Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
Am J Trop Med Hyg 74:554-63. 2006..This raises the possibility of differences in the mechanisms of malaria virulence between sub-Saharan Africa and Asia... - Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and diseaseMahamadou A Thera
Bandiagara Malaria Project, Malaria Research and Training Center, University of Bamako, Mali
J Infect Dis 192:1823-9. 2005..CONCLUSIONS. In this setting of low antifolate resistance, TS was highly effective in preventing falciparum malaria infection and disease and did not appear to select for SP-resistant parasites... - Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosettingJ Alexandra Rowe
Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, United Kingdom
Proc Natl Acad Sci U S A 104:17471-6. 2007..falciparum rosetting. This work provides insights into malaria pathogenesis and suggests that the selective pressure imposed by malaria may contribute to the variable global distribution of ABO blood groups in the human population... - A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIVJoep J G van Oosterhout
Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
J Acquir Immune Defic Syndr 39:626-31. 2005..These should also assess benefit in patients receiving antiretroviral therapy...
Research Grants
- TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWICHRISTOPHER PLOWE; Fiscal Year: 2007..These studies are expected to add to our knowledge of the molecular basis of antifolate-resistant malaria and to provide information of direct and immediate relevance to HIV and malaria control policies in Africa. ..
- Clinical trial of chloroquine combinations in MalawiCHRISTOPHER PLOWE; Fiscal Year: 2007..Results of the proposed studies will also inform malaria treatment policies in other countries where chloroquine is still used or has recently been discontinued. ..
- TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWICHRISTOPHER PLOWE; Fiscal Year: 2003....
- DRUG-RESISTANT MALARIA IN MALAWICHRISTOPHER PLOWE; Fiscal Year: 2002..abstract_text> ..